Clinical trials
14 active studies led by CanSino Biologics Inc., of 41 in all
Source: ClinicalTrials.gov, Studies with CanSino Biologics Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show CanSino Biologics Inc. in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by CanSino Biologics Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: Wikidata, Company record Q91016085. Retrieved 13 Nov 2026.
14 active studies led by CanSino Biologics Inc., of 41 in all
Source: ClinicalTrials.gov, Studies with CanSino Biologics Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies CanSino Biologics Inc. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with CanSino Biologics Inc. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show CanSino Biologics Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets CanSino Biologics Inc. is in.
Stories on the topics CanSino Biologics Inc. works in.
Keeping the airway open is the first step in saving a life. More than half of deaths in low- and…
Read
More than 5 billion people lack access to safe, affordable medical oxygen. COVID-19 exposed gaps in…
Read
An estimated 936 million adults have obstructive sleep apnoea, and most are undiagnosed. CPAP machines, oral…
Read